Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease

BACKGROUND: In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and the alternative androgen-signalling-targeted inhibitor. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Hiroyoshi, Castellano, Daniel, de Bono, Johann, Sternberg, Cora N, Fizazi, Karim, Tombal, Bertrand, Wülfing, Christian, Foster, Meredith C, Ozatilgan, Ayse, Geffriaud-Ricouard, Christine, de Wit, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521736/
https://www.ncbi.nlm.nih.gov/pubmed/33738495
http://dx.doi.org/10.1093/jjco/hyab028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521736/
https://www.ncbi.nlm.nih.gov/pubmed/33738495
http://dx.doi.org/10.1093/jjco/hyab028

Ejemplares similares